BIBLIOGRAFIA
1. Dirks, J., Remuzzi, G., Horton, S. et all. in Disease Control Priorities in Developing Countries (eds Jamison, D. T. et al) 695-706 (Oxford University Press and the World Bank, New York, 2006)
2. Perico, N., Benigni, A., Remuzzi, G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nature Rev Drug Discov, 7: 936-953, 2008
3. Ruggenenti P, Perna A, Gherardi G, et all: Renal function and equirement for dialysis in chronic nephropathy patients on long-term
ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352: 1252-1256, 1998
4. Ruggenenti P, Perna A, Benini R, et all: In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of timedependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc
Nephrol 10: 997-1006, 1999
5. Locatelli F, Tucci B, Del Vecchio L. Rallentare la progressione del danno renale oggi. La malattia renale cronica: un rilevante problema personale, familiare e sociale. G Ital Nefrol 2012; 29 (S58): S54-S60
6. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372 (9638): 547-53
7. Heerspink HJ, Ninomiya T, Zoungas S, et al.. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and metaanalysis of randomised controlled trials. Lancet 2009;373: 1009–1015
8. Levin NW, Kotanko P, Eckardt KU, Kasiske BL, Chazot C Cheung AK, Redon J, Wheeler DC, Zoccali C, London GM. Blood pressure in chronic kidney disease stage 5D report from a Kidney Disease: Improving Global Outcomes controversies conference.
Kidney Int 2010;77:273–284